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Summary
Objective: To examine the association of genetic variation in key players in the Wnt signaling pathway with aspects of osteoarthritis (OA) in
two population-based cohort studies: the Rotterdam Study and the Chingford Study.
Methods: Radiographic OA (ROA) was deﬁned as a Kellgren/Lawrence score (K/L) score 2 for the knee and hip. Total hip replacement
(THR) was scored. Hand OA was deﬁned as presence of ROA (K/L 2) in two out of three hand joint groups [distal interphalangeal
(DIPs), proximal interphalangeal (PIPs), ﬁrst carpometacarpal (CMC1)/trapezio-scaphoid joint (TS)] of each hand. The concentration of urinary
C-terminal cross-linked telopeptide of type II collagen (CTX-II) was standardized to the total urine creatinine. Genotypes for the amino acid
variants, Arg200Trp and Arg324Gly of Frizzled-Related protein gene (FRZB), Ala1330Val of Low-density lipoprotein receptor-related protein
5 (LRP5) and Ile1062Val of Low-density lipoprotein receptor-related protein 6 (LRP6), were obtained using the Taqman allelic discrimination
assay. A meta-analysis was performed for the FRZB Arg324Gly polymorphism and hip- and knee-OA using RevMan version 4.3.
Results: No consistent associations were observed between the FRZB, LRP5 and LRP6 amino acid variants and radiographic hip-, knee-, or
hand-OA or THR, in either study population. While power was limited for most studies to date, a meta-analysis of all published studies regard-
ing the FRZB Arg324Gly polymorphism was performed for hip- and knee-OA seperately. This showed no signiﬁcant associations between the
Gly324 allele and risk for hip- or knee OA, although there was large heterogeneity between studies for hip OA in females.
Conclusion: No association was seen between FRZB, LRP5 and LRP6 variants with radiographic osteoarthritic outcomes in two population-
based cohorts. In future studies, increased power and standardization of OA-phenotypes are highly recommended for replication studies and
to allow meta-analysis.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a chronic, age-related, degenerative
disease of the synovial joints. It is characterized by cartilage
degradation, formation of osteophytes, subchondral sclero-
sis and synovitis1. The etiology of OA is multifactorial, i.e.,
environmental and genetic factors play an important role
in the development of OA. Primary OA has an estimated
heritability of 40% for the knee, 60% for the hip and 65%
for the hand2. This means that a substantial proportion of
variation in risk for OA can be attributed to genetic variation,
i.e., polymorphisms in genes involved in the etiology of OA.
The vast majority of the genes are unknown and their*Address correspondence and reprint requests to: Dr Joyce JB
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Room Ee571, Erasmus MC, MC PO Box 1738, 3000 DR
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1141identiﬁcation could explain much of the pathogenesis of
OA, which at the moment remains unclear.
Evidence is accumulating, showing that the Wnt signaling
pathway is involved in cartilage degeneration and OA3e11.
Several Wnt signaling proteins were shown to play an im-
portant role in regulating many aspects of chondrogenesis
and skeletal development, including limb formation and
osteoblast maturation4. Genes encoding proteins of the
Wnt signaling pathway are therefore interesting candidates
to search for common genetic variants that could contribute
to risk for OA.
Frizzled-Related protein gene (FRZB) is a key player in the
Wnt signaling pathway with regard to cartilage metabolism
and OA4,6,7,10e12. Several studies have investigated the re-
lationship between OA and two polymorphisms in the
FRZB gene: the FRZB Arg200Trp and Arg324Gly variants.
Loughlin et al. observed in female carriers of the FRZB
Gly324 allele an increased risk for total hip replacement
(THR)6. However, subsequent studies have yielded conﬂict-
ing results7,11,13e15. This could partially be explained by the
1142 J. M. Kerkhof et al.: ROA and FRZB, LRP5, and LRP6 polymorphismsvariety of OA-deﬁnitions across studies. In general, many dif-
ferent phenotypes are used as endpoints in genetic studies
of OA and those on FRZB are no exception. Such pheno-
types may vary from clinical endpoints such as THR to
biochemical assessments [such as with C-terminal cross-
linked telopeptide of type II collagen (CTX-II)], and include
radiographic deﬁnitions of OA as deﬁned by the Kellgren/
Lawrence (K/L) score at several possible sites (knee, hip
or hand), and be even based on composites and/or sub-phe-
notypes from this score. Furthermore, individual studies
might be underpowered, which could be a reason why true
associations might not be observed. A meta-analysis could
help to overcome such limitations and document the true
effect (if any) of such genetic variants on the risk of OA.
In three papers, the relationship between the rare FRZB
‘‘Trp200eGly324’’ haplotype (frequency of 0.6e5.0%) and
OA has been studied6,11,13. They found that female carriers
of this haplotype have an increased risk of THR6, severe
JSN of the hip11 and clinical knee OA13 further supporting
a role for FRZB variants in OA. In addition, Gordon
et al.16 showed recently that the FRZB Trp200 allele was
associated with a decreased risk of osteolysis after total
hip-arthroplasty. In this study, we examined the relationship
between combined genotypes (FRZB Arg200Trp and
Arg324Gly variants) and hip- and knee-OA.
Low-density lipoprotein receptor-related protein 5 and 6
(LRP5 and LRP6) are two known co-receptors for Wnt
proteins17. Since Wnt signaling is involved in cartilage
degeneration and OA3e11 and LRP5 and LRP6 are key
players in the Wnt signaling pathway17,18, these genes
are logical candidate genes to study in relation to OA.
Several studies have shown that genetic variation in the
LRP5 and LRP6 genes is associated with bone-related
outcomes19e26. With respect to OA, studies of LRP5 and
LRP6 polymorphisms are scarce. One study observed
a common haplotype of the LRP5 gene, to be associated
with an increased risk of knee OA27.
In the present study, we examined the association of the
Arg200Trp and Arg324Gly variants of FRZB, the LRP5
Ala1330Val variant and the LRP6 Ile1062Val variant with
the risk of radiographic hip-, knee- and hand-OA, THR,
and urinary CTX-II levels. We investigated these associa-
tions in two population-based cohort studies: the Rotterdam
Study and the Chingford Study. In addition, a meta-analysis
was performed for the FRZB Arg324Gly polymorphism and
hip- and knee-OA.
Materials and methodsTHE ROTTERDAM STUDYThe Rotterdam Study is a large prospective population-based cohort study
of men and women aged 55 years and older. The study design and rationale
are described elsewhere in detail28. In summary, the objective of the study is
to investigate the determinants, incidence and progression of chronic dis-
abling diseases in the elderly28. Depending on the OA outcome studied, there
were 2685e3001 subjects with data available for OA outcomes. For example,
for THR we had data available for 2998 subjects. The medical ethics commit-
tee of Erasmus University Medical School approved the study and written in-
formed consent was obtained from each participant.
Clinical examination: height and weight were measured at baseline exam-
ination with the subject in a standing position with indoor clothing without
shoes. The presence of knee/hip/hand pain (‘‘did you have joint complaints
of your right/left knee/hip/hand during the last month’’) was asked during
the home interview at baseline29,30. The deﬁnitions for coronary heart
disease, diabetes and lower limb disability are described elsewhere31e33.THE CHINGFORD STUDYThe Chingford Study is a prospective population-based longitudinal cohort.
The Chingford Study includes 1003 women derived from the age/sexregister of a large general practice (n> 11,000) in North London, who are
representative of the general UK population in terms of weight, height and
smoking characteristics34. The study design and rationale are described
elsewhere in detail35e37.
Clinical examination: all anthropometrical measurements were taken in
a standardized manner, measured in standing position. Knee and hip pain
were deﬁned as having pain on most days of the month in at least one
episode, in one or both joints during the last year.ASSESSMENT OF RADIOGRAPHIC OSTEOARTHRITIS (ROA)Radiographs were scored for the presence of a THR and ROA of the hip,
knee and hand according to the K/L score38. Knee and hip ROA were
deﬁned as a K/L score 2 of one or both joints29,39. Also, a joint space width
(JSW) in one or both hips 1.5 mm was deﬁned as ROA. Hand OA was
deﬁned as presence of a K/L score 2 in two out of three hand joint groups
[distal interphalangeal (DIPs), proximal interphalangeal (PIPs), ﬁrst carpome-
tacarpal (CMC1)/trapezio-scaphoid joint (TS)] of each or both hands30. Fur-
thermore, in a subgroup of the Rotterdam Study, we used a K/L score 3 of
the knee and K/L score 2 of the metacarpophalangeal (MCP) joints of the
hand as additional outcomes for severe OA. Clinical OA was deﬁned as hav-
ing a K/L 2 plus joint complaints in that speciﬁc joint.BIOCHEMICAL MEASUREMENTUrinary CTX-II was measured as described before29,40. The concentration
of CTX-II (ng/L) was standardized to the total urine creatinine (mmol/L).GENOTYPINGGenotyping of both the Rotterdam Study and the Chingford Study was
done by the Genetic Laboratory of the Department of Internal Medicine in
Rotterdam. Genomic DNA was extracted from peripheral venous blood
samples according to standard procedures. Genotypes were determined
using the Taqman allelic discrimination assay. The Assay-by-Design service
(www.appliedbiosystems.com) was used to set up a Taqman allelic
discrimination assay for the FRZB Arg324Gly, the FRZB Arg200Trp, the
LRP5 Ala1330Val and the LRP6 Ile1062Val polymorphisms. The primers
and probes used are available on request and conditions of the assay
were as previously described26.STATISTICAL ANALYSISAllele frequencies were estimated by allele counting and
HardyeWeinberg equilibrium (HWE) was tested using a c2 test. For rea-
sons of power, homozygous and heterozygous carriers of the risk alleles
were pooled for estimation of the odds ratio (OR) for all SNPs studied.
Differences in baseline characteristics and CTX-II levels were evaluated
by analysis of co-variance (ANCOVA). In order to compare the CTX-II
levels in the two cohorts, sex-speciﬁc standard deviation (SD) scores
were calculated separately for each subject in each cohort as described
elsewhere in detail41. ORs, crude and adjusted for age and body mass in-
dex (BMI), were estimated from logistic regression for cross-sectional
analysis of all the binary OA variables. Linkage Disequilibrium (LD) be-
tween the Arg200Trp and Arg324Gly FRZB SNPs was estimated by D0
and r2 and was calculated using Haploview. SPSS version 11.0 (SPSS
INC., Chicago, USA) was used to construct combined genotypes. Interac-
tion between the different SNPs was tested using the multi-locus model
implemented in FAMHAP and is described elsewhere in detail42. Power
calculations were performed with the program PS (http://biostat.mc.van-
derbilt.edu/twiki/bin/view). Stratiﬁcation according to gender was per-
formed. A P-value of 0.05 was considered signiﬁcant. If not stated
otherwise, we used SPSS version 11.0 software for all analyses.
Power considerations: for FRZB Arg324Gly, LRP5 Ala1330Val and LRP6
Ile1062Val polymorphisms, we performed power calculations for detectable
effect sizes in our study at b¼ 0.80 and a¼ 0.05.META-ANALYSISWe conducted a meta-analysis of data from all published studies
regarding the FRZB Arg324Gly polymorphism, in order to assess whether
the Gly324 allele is associated with increased risk for hip- or knee OA.
ORs for the individual studies were estimated using the number of
subjects and allele frequencies presented in the papers. Forest plots
were created using RevMan Analyses version 1.043. By eyeballing and
using the Q-statistic (ManteleHaenszel c2) and I2-statistic, heterogeneity
between studies was assessed. A p-value 0.10 was considered signiﬁ-
cant for the Q-statistic. The DerSimonian and Laird test was used in
RevMan Analyses version 1.043 to estimate an OR in case of
1143Osteoarthritis and Cartilage Vol. 16, No. 10heterogeneity (random-effects model), otherwise a ManteleHaenszel test
was performed (ﬁxed-effect model). Analyses were performed separately
for males and females, since positive studies only found an association in
females. In the case more than one deﬁnition of hip- or knee-OA occurred
in one study, only the deﬁnition for which most power was observed, was
included in the meta-analysis.ResultsGENOTYPINGIn the Rotterdam Study, all genotypes were in HWE.
However, in the Chingford Study we observed a HWE
deviation for LRP5 Ala1330Val and LRP6 Ile1062Val geno-
type distributions, but this was borderline signiﬁcant (0.03
and 0.05, respectively). To exclude genotyping errors we
re-genotyped all homozygote carriers of the LRP5 Val1330
allele and the LRP6 Val1062 allele, but no discrepancies
were detected. While all genotyping was done at the
same laboratory, it is unlikely that genotyping errors are
the cause of the slight imbalance in HWE in the Chingford
Study. Allele frequencies for all polymorphisms where
similar to the ones found in previous studies on
Caucasians6,7,11,14,27.BASELINE CHARACTERISTICSCharacteristics of the Rotterdam Study and the Chingford
Study are shown in Table I. In women, there were no
associations between these characteristics and the two
studied polymorphisms in the FRZB gene, neither in the
Rotterdam Study nor in the Chingford Study (data not
shown). For males in the Rotterdam Study, carriers of the
FRZB Gly324 allele were on average 1 year older as the
non-carriers (data not shown).OSTEOARTHRITIC OUTCOMESTable II shows no consistent signiﬁcant associations
between the FRZB Gly324 variant and hip-, knee-, or
hand-OA outcome measures in the Rotterdam, nor in
the Chingford Study. Adjusting for co-morbidity factors
such as lower limb disability, coronary heart disease
and diabetes did not change these results. There were
no signiﬁcant associations between the three other stud-
ied variants, FRZB Trp200, LRP5 Ala1330, LRP6 Ala1062,
and hip-, knee- or hand-OA (Supplementary Tables
IVeVI) and there were no associations between the
FRZB, LRP5 and LRP6 variants and other osteoarthritic
outcomes such as JSW of the hip, clinical OA, OA inTable
Characteristics of the Rotterdam Study and the Chingfo
Rotterdam Stud
n Males/n Females n¼ 1765 males
Age (years)* 67.1 7.3
Height (cm)* 175.1 6.7
Weight (kg)* 79.1 10.5
BMI (kg/m2)* 25.8 2.9
No. THR cases/total (%) 18/1276 (1.4)
No. Hip OA cases/total (%) 113/1276 (8.9)
No. Knee OA cases/total (%) 164/1063 (15.4)
No. Hand OA cases/total (%) 267/1329 (20.1)
CTX-II levels (ng/mmol) 142.8
NA¼ not applicable.
*Values are averages with SDs.the MCP joints of the hand and a K/L 3 for the knee
as a proxy for severe OA. Similarly, no associations
were observed between the genetic variants and THR, al-
though power was limited.
We next examined CTX-II levels as a measure of
generalized cartilage degradation. As shown in Fig. 1, in
the Rotterdam Study, female carriers of the FRZB Gly324
allele had 0.32 SD lower levels of CTX-II (P¼ 0.002), while
a similar non-signiﬁcant trend was seen in males with 0.13
SD lower levels for Gly324 carriers. In the Chingford Study,
we also observed a similar e though not signiﬁcant e trend
with 0.14 SD lower CTX-II levels in FRZB Gly324 carriers.
When we combined males and females from the Rotterdam
Study, and females from the Chingford Study according to
SD scores, carriers of the FRZB Gly324 allele had 0.29
SD lower CTX-II levels (P¼ 0.001).
For alleles of the FRZB Arg200Trp and Arg324Gly
polymorphisms we could not estimate haplotypes because
LD was too low (D0 ¼ 0.06; r2¼ 0.003 in the Rotterdam
Study). We therefore analyzed combined genotypes and
compared the combination of Trp200 and Gly324 carriers
with non-carriers of these two variants. There were no
signiﬁcant associations for hip- or knee-OA in the
Rotterdam Study or the Chingford Study. In females of the
Rotterdam Study, we observed an OR of 0.94 for hip OA
[95% conﬁdence interval (CI) 0.44e2.01] and 1.33 for
knee OA (95% CI 0.79e2.22) and in the Chingford Study
we observed an OR of 0.46 (95% CI 0.17e1.24) for hip
OA and 1.29 for knee OA (95% CI 0.58e2.96), however,
for both studies power was very limited. In the Rotterdam
Study, we constructed a multiple locus association model
incorporating all four polymorphisms in the three genes of
the Wnt signaling pathway to test for possible interactions.
No signiﬁcant interactions between the polymorphisms in
relation to OA endpoints were observed (data not shown).POWER CONSIDERATIONSWe calculate power for all published studies and our own
study (see Table III). For the FRZB Arg324Gly polymor-
phism we had 80% power to detect risks of at least 1.6
for knee OA in females of the Rotterdam Study and a risk
of 1.9 in the Chingford Study. For females in the Rotterdam
Study, we had 80% power to detect risks of 1.9 for hip OA
and 1.6 for hand OA. For THR we had 80% power to detect
a risk of 2.6, indicating very limited power in our study to
detect the originally reported OR of 1.5 for THR by FRZB
genotype6. For the LRP5 and LRP6 variants we had higher
power, given the higher allele frequencies. For example, forI
rd Study for the FRZB Arg324Gly polymorphism
y Chingford Study
n¼ 2448 females n¼ 780 females
68.0 7.9 64.2 6.2
161.9 6.5 160.6 6.1
70.1 11.1 69.1 12.4
26.8 4.1 26.9 4.7
62/1722 (3.6) NA
168/1722 (9.8) 245/750 (32.7)
479/1622 (29.5) 291/773 (37.6)
600/1672 (35.9) 100/636 (15.7)
209.4 227.9
Fig. 1. CTX-II levels by FRZB Arg324Gly genotype of males and
females of the Rotterdam Study and of females of the Chingford
Study. Values are adjusted for age and BMI.
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1144 J. M. Kerkhof et al.: ROA and FRZB, LRP5, and LRP6 polymorphismsknee OA in females in the Rotterdam Study, we could
detect (with 80% power) an OR of 1.5 for the LRP5 variant
and an OR of 1.4 for the LRP6 variant (data not shown). In
the Rotterdam Study and the Chingford Study we had very
low power to investigate the role of the rare FRZB combined
genotype and OA. In the Rotterdam Study, we had 80%
power to detect a OR of 2.3 in females for hip OA, in the
Chingford Study this was a OR of 2.5.META-ANALYSISIn Table III some characteristics of all published studies
are shown that were considered for the meta-analysis,
including our own data from the current study. For the
FRZB Arg324Gly polymorphism, the forest plots for hip
OA and knee OA are depicted in [Fig. 2(A) and (B)], respec-
tively. Large heterogeneity was observed between the
studies on hip OA in females reﬂected by a Q-statistic of
16.69 (df¼ 5), with a P-value of 0.005 and an I2 of 70%.
Therefore, a random-effects analysis was performed for
this phenotype. This analysis showed no evidence of
association between the FRZB Gly324 allele and hip OA in
females (combined effect estimate OR 1.09, 95% CI
0.80e1.47, P¼ 0.58). For knee OA no large heterogeneity
between studies was observed, and so both ﬁxed- and
random-effect analysis were performed. Both analyses
showed no evidence of association between the Gly324
allele and knee OA in males and females (combined effect
estimate OR 1.04, 95% CI 0.89e1.20, P¼ 0.63).Discussion
The present study showed that in two population-based
cohort studies no consistent associations were observed
between selected polymorphisms in the FRZB, LRP5 and
LRP6 genes and several measures of OA including, radio-
graphic hip-, knee- and hand-OA and THR. A meta-analysis
of all published studies and including our own data
indicated no evidence of association between the FRZB
Gly324 allele and hip- or knee-OA, although large
Table III
Overview of published studies on the relationship of the FRZB Arg324Gly polymorphism with OA outcomes
OA 
Phenotypes Hip OA Knee OA Hand OA
Generalized 
OA
CTX-II 
levels
THR RadiographicOA Power‡
Clinical 
OA
Radiographic 
OA Power‡
Clinical 
OA
Radiographic 
OA Radiographic
Author and study population (n) Case–control/
cohort M F M F M F M F M F M F M F M F M F M F
Loughlin et al.6 Oxford (n = 1696) Case–control 1.9 1.8 NA NA
Min et al.7 Rotterdam Study (n = 1369) Cohort NA NA NA NA
Min et al.7 GARP (n = 382) Family study* NA NA NA NA
Lories et al.14 Leuven (n = 314) Case–control NA 2.8 NA NA
Lane et al.11 SOF (n = 4706) Cohort NA 1.5 NA NA
Valdes et al.13 Nottingham/Oxford (n = 1202) Case–control† NA NA 2.0 2.2
Rodriguez et al.15 Spanishpatients (n = 1123) Case–control 2.5 2.2 3.1 2.1
Kerkhof et al. Rotterdam Study (n = 4472) Cohort 2.2 2.0 2.0 1.6
Kerkhof et al. Chingford Study (n = 814) Cohort NA 1.9 NA 1.8
SOF = Study of Osteoporotic Fractures, M = males, F = females, TKR = total knee replacement, CTX-II = urinary CTX-II levels. 
*One thousand eighty two control subjects from the Rotterdam Study are shared between that study and the Rotterdam Study described in this paper.
†One hundred and eighty five female control subjects from Oxford are shared between that study and the original study by Loughlin et al.
Not studiedNo association found Significantly increased risk Gly324 allele Significantly decreased risk Gly324 allele
‡Power is expressed as ORs that can be detected with beta = 80     and alpha = 0.05.
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*1Joint space narrowing is used as definition of hip OA. Other hip OA phenotypes are excluded
from the analysis. 
*2/3A Kellgren/Lawrence score ≥ 2 is used as definition of hip OA. The phenotype total hip
replacement is excluded from the analysis. 
Author
Loughlin et al.6
Lories et al.14
Lane et al.11*1
Rodriguez-Lopez et al.15
Kerkhof et al. (Rotterdam Study)*2
Kerkhof et al. (Chingford Study)*2
Total (95% CI) females
Odds ratio (random-effect) Odds ratio (random-effect)
95% Confidence Interval 95% Confidence Interval
0.1 0.2 0.5 2 5 10
Loughlin et al.6
Rodriguez-Lopes et al.15
Kerkhof et al. (Rotterdam Study)*3
Total (95% CI) males
a
1.59 [1.14, 2.23]
1.02 [0.55, 1.88]
1.36 [1.05, 1.76]
1.25 [0.76, 2.07]
0.98 [0.66, 1.46]
0.52 [0.33, 0.84]
1.09 [0.80, 1.47]
0.73 [0.48, 1.10]
0.90 [0.52, 1.55]
1.21 [0.78, 1.88]
0.92 [0.68, 1.26]
1.06 [0.87, 1.29]Overall estimate (95% CI) males and females
1
Odds ratio (fixed-effect) Odds ratio (fixed-effect)
95% Confidence Interval 95% Confidence Interval
1.44 [0.94, 2.19]
0.94 [0.57, 1.57]
1.12 [0.86, 1.47]
0.80 [0.54, 1.20]
1.07 [0.89, 1.29]
0.1 0.2 0.5 2 10
0.92 [0.61, 1.39]
1.19 [0.61, 2.32]
1.04 [0.69, 1.57]
1.01 [0.78, 1.32]
1.04 [0.89, 1.20]
Total (95% CI) females
Valdes et al.13
Rodriguez-Lopez et al.15
Kerkhof et al. (Rotterdam Study)*1
Kerkhof et al. (Chingford Study)*1
Author
Valdes et al.13
Rodriguez-Lopez et al.15
Kerkhof et al. (Rotterdam Study)*1
Total (95% CI) males
Overall estimate (95% CI) males and females
*1A Kellgren/Lawrence score ≥ 2 is used as definition of knee OA. The phenotype total knee replacement
is excluded from the analysis. 
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Fig. 2. Forest plot of studies regarding the FRZB Arg324Gly polymorphism. (A) Forest plot of studies regarding FRZB Arg324Gly
polymorphism and hip OA. (B) Forest plot of studies regarding FRZB Arg324Gly polymorphism and knee OA.
1146 J. M. Kerkhof et al.: ROA and FRZB, LRP5, and LRP6 polymorphismsheterogeneity was observed between studies concerning
hip OA in females. Recently, Loughlin et al. observed in
957 females the Gly324 variant of the FRZB gene to be as-
sociated with a 1.5 times higher risk of THR6. In our study,
however, we did not observe an increased risk for THR bygenotype for the FRZB Arg324Gly or FRZB Arg200Trp
polymorphisms, although power in our population was
very limited for purposes of replication of this phenotype.
For other hip-related OA outcome measures such as the
JSW and the K/L score, we had somewhat higher power,
1147Osteoarthritis and Cartilage Vol. 16, No. 10but we could not detect an association or a trend in the pre-
dicted direction. Within the Rotterdam Study we can only
exclude risks of 2.0 for hip ROA based on power calcula-
tions, while Loughlin et al. found an OR of 1.5 for the
FRZB Gly324 allele (and then for THR, rather than hip OA
deﬁned by radiography). Therefore, the lack of power, espe-
cially for hip OA, could be one of the reasons for our nega-
tive ﬁndings. Alternatively, the difference in severity of OA
(hip replacement cases vs radiological deﬁned milder OA
in our study) could be another reason for the negative ﬁnd-
ings. Lastly, negative ﬁndings could be based on confound-
ing due to co-morbidity factors. However, in the Rotterdam
Study no differences in risk for OA were observed after ad-
justing our results for co-morbidity factors such as lower
limb disability, coronary heart disease and diabetes.
We also explored the association withmore clinical/severe
deﬁnitions of OA in a subset of our subjects. We identiﬁed
a subgroup with a JSW 1.5 mm of the hip, a K/L score 3
of the knee, current pain in the hip/knee/hand coinciding with
ROA of that joint and K/L score 2 of the MCP joints of the
hand as a proxy for severe hand OA30. However, again there
were no associations observed between these more severe
and clinical phenotypes and the four polymorphisms. In line
with our observation, also three other reports found conﬂict-
ing results for the role of the FRZB Arg324Gly polymorphism
in OA, although each study used a different deﬁnition of
OA7,11,14. This highlights a general difﬁculty in genetic
studies of OA: the lack of consensus on OA-deﬁnitions or
outcomes to use and how to compare different joint sites
for replication44. In Table III, we compared OA endpoints
used in different studies on the FRZB Arg324Gly polymor-
phism. This table shows: (1) that different studies used
different outcomes, (2) only very few studies analyzed the
same phenotypic OA outcome, and (3) that there is no
consistency in the results for this association. Considering
that results are conﬂicting and power of individual studies
is limited, a meta-analysis may help in determining the true
effect sizes if any. The meta-analysis of all published studies
and including our results showed no evidence of association
between the FRZB Gly324 allele and hip- or knee-OA. In the
process of the meta-analysis, we had difﬁculty with handling
the different OA-phenotypes used in the published studies.
For example, for hip OA it was necessary to combine both
clinical and ROA outcomes, resulting in a large heterogene-
ity between studies. Therefore, the power becomes lower to
observe an association. Recently, general recommenda-
tions have been published by working groups of HuGEnet
and NCIeNHGRI45e47 for replication studies in genetic
epidemiology studies. One of the recommendations was to
preferably investigate the same or a very similar phenotype
in replication studies and for genetic studies in OA this repre-
sents a substantial challenge as is discussed above in some
more detail.
Previously, Min et al.7 published a paper regarding the
FRZB Arg324Gly polymorphism and OA using a random
sample of 1369 subjects of the Rotterdam Study. They
found a signiﬁcant association of the FRZB Arg324Gly
polymorphism with generalized OA. In the present study,
apart from testing additional polymorphisms, we focused
more on the many different joint sites of OA, including hip-
, knee- and hand-OA and CTX-II measurement. Further-
more, we used more subjects of the Rotterdam Study
(4472 instead of 1369, average overlap between the study
of Min et al. and the Rotterdam Study for hip-, knee- and
hand-OA is 79%), thereby increasing power.
In the Chingford Study and in the Rotterdam Study we
used a cut-off point for the K/L score of the hip of grade2, which is considered the golden standard for hip OA48.
However, the prevalence of hip OA was three times higher
in the Chingford Study compared with the Rotterdam Study
when using grade 2þ. This is highly likely due to the fact
that agreement between observers for the grading of OA
is rather low, particularly for hip OA48. This is a problem
we cannot overcome at this moment and is a general
problem for all OA-studies. The differences in K/L scoring
between different cohorts is becoming apparent because
of the population-based design of our study. It was picked
up due to frequency differences between the two cohorts.
These frequency differences cannot be observed in
a caseecontrol study.
Cartilage degradation is one of the main characteristics of
OA and is commonly assessed by the JSW measurement.
However, signiﬁcant cartilage degradation has to occur in
order to visualize a reduction in JSW on radiographs49.
Biochemical markers may be more sensitive than ra-
diographs to pick up early changes in the cartilage50,51.
CTX-II levels are a biochemical marker of cartilage degra-
dation29. CTX-II levels are elevated in diseases that are
characterized by increased cartilage turnover such as rheu-
matoid arthritis and OA49,50,52. We observed a highly signif-
icant association with the FRZB Arg324Gly polymorphism
and CTX-II levels in females of the Rotterdam Study, which
suggests a protective effect for OA (assessed by CTX-II
levels) for carriers of the FRZB Gly324 allele. The Chingford
Study showed a non-signiﬁcant trend in the same direction.
This ﬁnding is counter-intuitive since previous research lead
to the hypothesis that carriers of the FRZB Gly324 allele are
less capable of antagonizing Wnt signaling6, which would
lead to a higher Wnt signaling in cartilage and hence, in
an increased risk of OA3,8e10. Although a false positive re-
sult due to multiple testing is still possible, the partial conﬁr-
mation in Chingford and overall signiﬁcance of the two
combined study populations makes this a less likely expla-
nation. It therefore suggests a true effect of FRZB genotype
on CTX-II levels but this observation still warrants further
validation in other cohorts.
One earlier report examined the relationship between poly-
morphisms in the LRP5 gene and OA and found an associa-
tion between a certain haplotype of the LRP5 gene and knee
OA27. In this study, we examined the relationship between
the LRP5Ala1330Val variant andOA. This is not a direct rep-
lication of the study of Smith et al.27. Previous research
showed that genetic variation in exon18of LRP5, in particular
the Ala1330Val variant, modulates Wnt signaling53, and
therefore the Ala1330Val variant is a promising variant to
study in relation to OA. In our study, we did not observe any
relation between the LRP5 Ala1130Val variant with knee-,
hip- and hand-OA or CTX-II levels in either cohort. Consider-
ing the earlier results of Smith et al. who studied other poly-
morphisms in this gene as we did, we cannot exclude that
the LRP5 gene does play a role in the pathogenesis of OA,
but if so perhaps through other variants than the Ala1330Val
variant. A tagging approach of the large LRP5 gene would be
most appropriate to investigate the role of this gene in the
pathogenesis of OA, however, we did not use this approach
in our study, which is a limitation of this study. To our knowl-
edge, we are the ﬁrst to study the relationship between the
LRP6 amino acid variant and OA. de Ferrari et al. showed
that the LRP6 Val1062 allele leads to a decreased beta-
catenin signaling54 and could therefore decrease the risk of
OA. However, we did not observe signiﬁcant associations
between this variant and osteoarthritic outcomes.
Lastly, we would like to discuss power issues. For
females in the Rotterdam Study, we had 80% power for
1148 J. M. Kerkhof et al.: ROA and FRZB, LRP5, and LRP6 polymorphismsthe FRZB Arg324Gly variant to detect risks of 2.0 for hip-OA
and 1.6 for knee-OA as deﬁned by the K/L score, while for
THR power was 2.6. For the LRP5 and LRP6 variants and
other osteoarthritic endpoints we had overall somewhat
higher power, given the higher allele frequencies. There-
fore, it is possible that in our study some true associations
were not detected due to lack of power, especially for
THR. Yet, we note that most previously published studies
on this association had very limited power and so a meta-
analysis of all published studies including our own results
could have overcome this problem, if this was the only
reason for missing the association in our study. However,
the meta-analysis failed to provide convincing evidence to
support an association of the FRZB Arg324Gly polymor-
phism with several OA endpoints, although for hip OA in
females, large heterogeneity existed between studies.
In conclusion, we studied polymorphisms in several key
players of the Wnt signaling pathway but did not observe
any association between the FRZB, LRP5 and LRP6 amino
acid variants with osteoarthritic outcomes in two population-
based cohorts. A meta-analysis for the FRZB Gly324 allele
showed no evidence of association with hip- or knee-OA.
This study underscores that more consensus is needed to
standardize phenotypes of interest in future genetic studies
of OA as well as increasing sample sizes. The recently
formed European Consortium to explore the genetics of
OA called Treat-OA (www.TreatOA.eu) has access to up
to 30,000 DNA samples and hopefully should be able to
overcome some of these issues in the near future.Conﬂict of interest
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